Certainity to conception

Ovarian Health Rejuvenation Pioneered

Since the 1950s, medical dogma has insisted women have a limited number of eggs from birth and therefore limited opportunities to conceive. This concept has perpetuated the idea of a biological clock as an immovable obstacle to getting pregnant, especially when compounded by advancing age and medical issues.

Every day, clinicians, embryologists, para-medics and others in the fertility community are working together to overcome fertility obstacles. They are seeking cutting-edge research and optimizing procedures in order to improve the odds for the one in six couples who needs medical help building a family. While technologies like IVF have helped millions, there remain millions more for whom infertility is still a reality. Incremental improvement is important, but innovation is required to meet the large unmet patient need – innovation that has the power to change that which we are capable of achieving.

Within the last ten years, a profound scientific discovery has overturned the long-held medical belief that women are born with a finite number of eggs that die over time. The discovery of egg precursor cells (immature egg cells inside a woman’s body) has the potential to offer new fertility treatment options.

Egg precursor cells are found in the protective outer layer of a woman’s ovaries, and therefore are not exposed to environmental insults. In 2012, a scientific paper published in Nature Medicine took the fertility world by storm, demonstrating that these egg precursor cells have the potential to regenerate and matured into fresh, young, healthy eggs. Not only does this mean that a woman is not born with a finite number of eggs, but that having a biological child may be possible for many who currently are unable. This discovery has the potential to be used to improve egg health, increase egg reserve and develop a potential next generation of IVF.

Poor egg health is one of the major reasons women who undergo IVF may be unsuccessful, and often is caused by a lack of the energy (mitochondria) needed for healthy egg and embryo development. This lack of energy is common as women age, but also can happen in younger women for a variety of reasons, such as reproductive disorders, environmental factors and other medical conditions. It has been shown in scientific literature that adding mitochondria to an egg may improve the success rates of IVF; however, before the discovery of egg precursor cells, women did not have a good source of their own mitochondria to use.

There is hope for those struggling with infertility. The global fertility community is engaged, motivated and passionate. The translation of scientific discoveries into treatment options takes time, effort and rigor, but this has not and will not deter innovators from seeking to fulfill their commitment to patients.

OvaSera from Seragen is the first big step in the direction of regeneration powered by autologous source. Standardized protocol perfected over thousands of patients and deeply personalized for patient specific comorbidities, Seragen is able to assist clinicians with the much needed impetus

Seragen is also developing other potential treatments to provide new treatment options to fertility patients.

Posted by: Srinivas Chari | Seragen

Recurrent Pregnancy Loss & Unexplained Infertility

Recurrent pregnancy loss remains “unexplained” in more than 50% of patients. Seragen network of fertility clinics now offer a new testing and reporting platform for the immunological evaluation of miscarriage and infertility. Our protocol can help guide the immune treatment with even more precision.

The protocol is developed by a team of reproductive immunologists alognwith Seragen team based on global best practices. Starting with the Reproductive Immunology Report we help identify the potential causes of infertility, estimate chances of successful live birth based on their customized artificial intelligence algorithm, and provides clinician with decision support for follow-up treatment for an improved chance of success.

Specific to recurrent pregnancy loss, Seragen battery of tests check for:

+uterine killer cells (NK cells)
+anti – HLA antibodies
+thrombophilia
+vitamin D levels
+folate levels
and more

Our unexplained infertility therapy is available at our exclusive network, offered by leading doctors.

Posted by: Srinivas Chari | Seragen

Stem Cells Led Regeneration Made Easier

Stem cells usage in fertility treatments is long considered useful for the regeneration power it lends to the target cell linegae, tissue or organ.

Telomerase activity historically considered corelated to longevity owing to empirical data is also now seen to be useful in regeneration.

Telomerase is an enzyme that is essential for the self-renewal and potential of different types of stem cells.

While the utility of stem cells can hardly be overemphasized, clinicians have struggled to harness its potential because of sources like bone marrow or fat tissue which often require a surgical procedure for collection. In addition allogenic sources pose immulogy, safety and rejection risks.

Latest research from Wake Forest Institute for Regenerative Medicine (WFIRM) researchers who were the first to identify that stem cells in human urine have potential for tissue regenerative effects, continue their investigation into the power of these cells. Human urine-derived stem cells can be easily isolated from urine samples which offers clear advantages over stem cells from other sources.

Seragen research team is exploring the regenerative significance of telomerase activity, particularly in terms of characteristic cell surface marker expression, multipotent differentiation capability, chromosomal stability, and safety of this ground breaking research. The findings may provide a novel perspective to evaluate the capacity of telomerase-positive human urine-derived stem cells to become a wide variety of other cell types, and to be used as an optimal cell source for stem cell therapy or cell-based tissue regeneration in treating infertility.

The autologous source and non-invasive collection method is suitable for rapid clinical translation.

Seragen engages only in autologous cell based point of care therapeutics as an intervention for treating specific infertility. All our therapeutics are purely autologous and safe.

Original Research Credit: WFIRM’s Yuanyuan Zhang, Ph.D, lead author of the paper published by Frontiers in Cell and Developmental Biology.

Posted by: Srinivas Chari | Seragen